How novel hormonal agents are changing treatment paradigms in advanced prostate cancer

9 Mar 2023Oncology

Anne Michael

This content is sponsored. It is intended for healthcare professionals only.

In October 2022, a webinar discussing updates on treatment paradigms in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) was held.

MPR-BAY-2022196 How novel hormonal agents are changing treatment paradigms in advanced prostate cancer

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.